Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intralesional steroid injections to prevent refractory anastomotic strictures in children with esophageal atresia
NL-OMON50430Phase 3Recruiting
- Sponsor
- Erasmus MC
- Start
- Oct 2019
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of triamcinolone in esophageal atresia (EA) and Esophageal stricture (2 arms), sponsored by Erasmus MC. Primary endpoint: Total number of dilations within 28-day intervals during study period. Started Oct 2019; status: recruiting.
02
Drugs
triamcinolone
03
Conditions
esophageal atresia (EA)Esophageal stricture
Beyond the preview
Go deeper on NL-OMON50430.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON50430.